Norris Medicines Ltd

Norris Medicines has announced its financial results for the quarter ending December 2024, revealing stable performance metrics. The company's evaluation score has remained unchanged over the past three months, indicating a consistent assessment of its position in the pharmaceuticals sector amidst ongoing market complexities.

Norris Medicines, a microcap pharmaceutical company, has gained significant attention in the stock market with its stock price reaching a 52-week high on November 14, 2024. Despite being given a Sell call by MarketsMOJO, the stock has consistently outperformed the sector and its moving averages, showcasing its potential for growth and strong returns for investors.

Norris Medicines, a microcap pharmaceutical company, reported a flat performance for the quarter ending June 2024, with a score of 0 compared to 3 in the previous quarter. Despite this, the company remains dedicated to providing affordable and high-quality medicines, with a strong pipeline of new products and ongoing investments in research and development. Investors should carefully consider all available information before making any decisions regarding Norris Medicines' stock.

Norris Medicines, a microcap pharmaceutical company, reported a flat performance in the quarter ending March 2024 with a score of 3 out of 10. However, the company's profit before and after tax, as well as earnings per share, were the highest in the last five quarters, indicating a positive trend in the near term. MarketsMOJO has given a 'Strong Sell' rating for the company's stock.

Norris Medicines, a microcap pharmaceutical company, has been making headlines for its impressive stock performance, reaching a 52-week high on February 5th, 2024. Despite being rated as a 'Sell' by MarketsMOJO, the company has shown a 98.63% increase in stock price compared to Sensex's 18.37% performance. With consistently trading above its moving averages, Norris Medicines is a promising player in the pharmaceutical industry.

Norris Medicines, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high of Rs.26.87 on February 2nd, 2024. The stock has outperformed the sector by 1.41% and gained 30.66% in the last 7 days. With a strong 1-year performance of 94.10%, Norris Medicines shows potential for growth in the pharmaceutical industry.

Norris Medicines, a microcap pharmaceutical company, has seen a 52-week high with its stock price reaching Rs. 25.59 on February 1st, 2024. The stock has gained 27.57% in the past 6 days and outperformed the sector by 4.15% today. It is currently trading higher than its moving averages and has shown a strong performance in the past year, highlighting its growth and potential in the industry.

Norris Medicines, a microcap pharmaceutical company, has been making headlines as its stock reached a 52-week high on January 31, 2024. The stock has outperformed the sector by 4.39% and gained 22.03% in the last 5 days. It is currently trading higher than its moving averages, indicating stability and strong potential for investors. However, MarketsMOJO has given a 'Sell' call for the stock, so investors should do their own research before making any decisions.

Norris Medicines, a microcap pharmaceutical company, has been making waves in the stock market with its stock price reaching a 52-week high on January 30th, 2024. Despite being rated as a 'Sell' by MarketsMOJO, the stock has outperformed the sector by 3.27% and is trading above its moving averages, showcasing its strong upward trend. With a 1-year performance of 65.43%, Norris Medicines has proven its potential for growth and is a stock to watch in the pharmaceutical industry.

Norris Medicines, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on January 29, 2024. The stock has outperformed the sector by 3.99% and has been trading consistently with a 1-year return of 65.07%. However, experts advise caution and thorough research before investing.

Norris Medicines, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on January 25th, 2024. Despite being rated as 'Sell' by MarketsMOJO, the stock has been outperforming the sector and its moving averages, showcasing its strong potential and growth in the industry. Investors are advised to do their own research before making any investment decisions.

Norris Medicines, a microcap pharmaceutical company, has been making headlines as its stock price reached a 52-week high on January 23, 2024. Despite being rated as 'Sell' by MarketsMOJO, the stock has outperformed the sector and its moving averages, showcasing a positive trend. With a remarkable growth of 52.02% in the past year, Norris Medicines is proving to be a strong player in the industry.

Norris Medicines, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high of Rs. 20.44 on January 20, 2024. The company has outperformed the sector by 1.71% and has been on a consecutive gain for the last two days, with a 7.06% increase in returns. It is currently trading higher than its moving averages and has outperformed the Sensex by a significant margin, showcasing its strong growth potential.

Norris Medicines, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on January 17, 2024. The company's stock has been consistently outperforming the sector and the overall market, with a 23.82% increase in the last 5 days alone. This can be attributed to its strong performance and positive market sentiment.

Norris Medicines, a microcap pharmaceutical company, has been making headlines for its impressive stock performance, reaching a 52-week high on January 16, 2024. With a 12.85% increase in returns and trading above all its moving averages, the company has shown consistent growth and outperformed the sector. Its 27.34% increase in stock price over the past year also highlights its potential in the pharmaceutical industry. While MarketsMOJO has given a 'Sell' call, it is important to do individual research before investing.

Norris Medicines, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on January 15, 2024. Despite a 'Sell' rating from MarketsMOJO, the stock has consistently outperformed the sector and shown a strong 1-year performance of 23.48%, indicating potential for growth in the industry.

Norris Medicines, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on January 10, 2024. The stock has outperformed the sector by 0.47% and has been on a consecutive gain for the past two days. However, it is important to conduct thorough research before making any investment decisions.

Norris Medicines has reported a 169.47% increase in net sales and a 21.31% growth in standalone net profit for the quarter ended September 2023, despite challenges faced by the pharmaceutical industry due to the pandemic. The company's operating profit and interest expenses also showed positive trends, indicating efficient management. MarketsMOJO may have given a 'Sell' call, but Norris Medicines has shown resilience and potential for growth.